Ming-Hsi Wang1,2, Omar Y Mousa1, Jessica J Friton1, Laura E Raffals1, Jonathan A Leighton3, Shabana F Pasha3, Michael F Picco4, Kelly C Cushing5,6, Kelly Monroe6, Billy D Nix6, Rodney D Newberry6, William A Faubion1. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 2. Gastroenterology, Mayo Clinic Health System in Mankato, Mankato, Minnesota, USA. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA. 5. Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA. 6. Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
INTRODUCTION: Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is a rare phenotype. We aimed to assess patients with UC-PSC or UC alone and describe differences in clinical and phenotypic characteristics, antitumor necrosis factor (TNF) therapy, and long-term clinical outcomes. METHODS: This retrospective multicenter cohort study included patients who received a diagnosis of UC from 1962 through 2015. We evaluated clinical factors associated with UC-PSC vs UC alone and assessed associations by using multivariable logistic regression models. RESULTS: Among 522 patients with UC, 56 (10.7%) had PSC. Compared with UC alone, patients with UC-PSC were younger (younger than 20 years) at diagnosis (odds ratios [OR], 2.35; adjusted P = 0.02) and had milder UC severity (adjusted P = 0.05), despite having pancolonic involvement (OR, 7.01; adjusted P < 0.001). In the biologics era (calendar year 2005 to 2015), patients with UC-PSC less commonly received anti-TNF therapy compared with patients with UC (OR, 0.38; adjusted P = 0.009), but their response rates were similar. Fewer patients with UC-PSC received corticosteroids (OR, 0.24; adjusted P = 0.005) or rectal 5-aminosalicyte acid (OR, 0.26; adjusted P < 0.001). Other differences were identified that were not statistically significant in a multivariable model: patients with UC-PSC more commonly were male, had lower rates of smoking, and had higher rates of colorectal cancer and colectomy. DISCUSSION: This study identified a unique phenotype of UC with concurrent PSC, which had different clinical behavior compared with UC only. These phenotypic characteristics can help identify high-risk patients with UC before PSC is diagnosed and guide different management and monitoring strategies.
INTRODUCTION:Ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) is a rare phenotype. We aimed to assess patients with UC-PSC or UC alone and describe differences in clinical and phenotypic characteristics, antitumor necrosis factor (TNF) therapy, and long-term clinical outcomes. METHODS: This retrospective multicenter cohort study included patients who received a diagnosis of UC from 1962 through 2015. We evaluated clinical factors associated with UC-PSC vs UC alone and assessed associations by using multivariable logistic regression models. RESULTS: Among 522 patients with UC, 56 (10.7%) had PSC. Compared with UC alone, patients with UC-PSC were younger (younger than 20 years) at diagnosis (odds ratios [OR], 2.35; adjusted P = 0.02) and had milder UC severity (adjusted P = 0.05), despite having pancolonic involvement (OR, 7.01; adjusted P < 0.001). In the biologics era (calendar year 2005 to 2015), patients with UC-PSC less commonly received anti-TNF therapy compared with patients with UC (OR, 0.38; adjusted P = 0.009), but their response rates were similar. Fewer patients with UC-PSC received corticosteroids (OR, 0.24; adjusted P = 0.005) or rectal 5-aminosalicyte acid (OR, 0.26; adjusted P < 0.001). Other differences were identified that were not statistically significant in a multivariable model: patients with UC-PSC more commonly were male, had lower rates of smoking, and had higher rates of colorectal cancer and colectomy. DISCUSSION: This study identified a unique phenotype of UC with concurrent PSC, which had different clinical behavior compared with UC only. These phenotypic characteristics can help identify high-risk patients with UC before PSC is diagnosed and guide different management and monitoring strategies.
Authors: Tom H Karlsen; Andre Franke; Espen Melum; Arthur Kaser; Johannes Roksund Hov; Tobias Balschun; Benedicte A Lie; Annika Bergquist; Christoph Schramm; Tobias J Weismüller; Daniel Gotthardt; Christian Rust; Eva E R Philipp; Teresa Fritz; Liesbet Henckaerts; Rinse K Weersma; Pieter Stokkers; Cyriel Y Ponsioen; Cisca Wijmenga; Martina Sterneck; Michael Nothnagel; Jochen Hampe; Andreas Teufel; Heiko Runz; Philip Rosenstiel; Adolf Stiehl; Severine Vermeire; Ulrich Beuers; Michael P Manns; Erik Schrumpf; Kirsten Muri Boberg; Stefan Schreiber Journal: Gastroenterology Date: 2009-11-26 Impact factor: 22.682
Authors: A Dignass; J O Lindsay; A Sturm; A Windsor; J-F Colombel; M Allez; G d'Haens; A d'Hoore; G Mantzanaris; G Novacek; T Öresland; W Reinisch; M Sans; E Stange; S Vermeire; S Travis; G van Assche Journal: Rev Gastroenterol Mex Date: 2015-03-10
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Natalie A Molodecky; Hashim Kareemi; Rohan Parab; Herman W Barkema; Hude Quan; Robert P Myers; Gilaad G Kaplan Journal: Hepatology Date: 2011-05 Impact factor: 17.425
Authors: M J Westerouen van Meeteren; B Hayee; A Inderson; A E van der Meulen; R Altwegg; B van Hoek; G P Pageaux; T Stijnen; D Stein; P W J Maljaars Journal: J Crohns Colitis Date: 2017-09-01 Impact factor: 9.071
Authors: Jimmy Z Liu; Johannes Roksund Hov; Trine Folseraas; Eva Ellinghaus; Simon M Rushbrook; Nadezhda T Doncheva; Ole A Andreassen; Rinse K Weersma; Tobias J Weismüller; Bertus Eksteen; Pietro Invernizzi; Gideon M Hirschfield; Daniel Nils Gotthardt; Albert Pares; David Ellinghaus; Tejas Shah; Brian D Juran; Piotr Milkiewicz; Christian Rust; Christoph Schramm; Tobias Müller; Brijesh Srivastava; Georgios Dalekos; Markus M Nöthen; Stefan Herms; Juliane Winkelmann; Mitja Mitrovic; Felix Braun; Cyriel Y Ponsioen; Peter J P Croucher; Martina Sterneck; Andreas Teufel; Andrew L Mason; Janna Saarela; Virpi Leppa; Ruslan Dorfman; Domenico Alvaro; Annarosa Floreani; Suna Onengut-Gumuscu; Stephen S Rich; Wesley K Thompson; Andrew J Schork; Sigrid Næss; Ingo Thomsen; Gabriele Mayr; Inke R König; Kristian Hveem; Isabelle Cleynen; Javier Gutierrez-Achury; Isis Ricaño-Ponce; David van Heel; Einar Björnsson; Richard N Sandford; Peter R Durie; Espen Melum; Morten H Vatn; Mark S Silverberg; Richard H Duerr; Leonid Padyukov; Stephan Brand; Miquel Sans; Vito Annese; Jean-Paul Achkar; Kirsten Muri Boberg; Hanns-Ulrich Marschall; Olivier Chazouillères; Christopher L Bowlus; Cisca Wijmenga; Erik Schrumpf; Severine Vermeire; Mario Albrecht; John D Rioux; Graeme Alexander; Annika Bergquist; Judy Cho; Stefan Schreiber; Michael P Manns; Martti Färkkilä; Anders M Dale; Roger W Chapman; Konstantinos N Lazaridis; Andre Franke; Carl A Anderson; Tom H Karlsen Journal: Nat Genet Date: 2013-04-21 Impact factor: 38.330